» Articles » PMID: 15642763

Role of Beta2 Adrenergic Receptors in Human Atherosclerotic Coronary Arteries

Overview
Journal Circulation
Date 2005 Jan 12
PMID 15642763
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Adrenergic regulation of coronary vasomotion is balanced between alpha1-adrenergic-mediated (alpha1-AR) constriction and beta2-adrenergic-mediated (beta2-AR) relaxation. This study aimed at assessing the role of beta2-ARs in normal, mildly atherosclerotic, and stenotic human coronary arteries.

Methods And Results: During intracoronary (IC) infusion of increasing doses of the beta2-AR agonist salbutamol (0.15, 0.3, and 0.6 mug/min) and the endothelial vasodilator acetylcholine (1, 3, and 10 microg/min), we measured (1) changes in lumen diameter (LD) by quantitative coronary angiography in 34 normal, 55 mildly atherosclerotic, and 42 stenotic coronary artery segments and (2) changes in average peak velocity (APV) and coronary blood flow (CBF) with the use of Doppler flow wire in 11 normal, 10 mildly atherosclerotic, and 11 stenotic coronary arteries. In 6 of 11 stenotic coronary arteries, the protocol was repeated after an IC bolus (12 microg/kg) of the alpha-adrenergic blocker phentolamine. In 6 of 11 normal coronary arteries, the protocol was repeated after an IC infusion (60 micromol/min) of N(G)-monomethyl-L-arginine (L-NMMA), a nitric oxide inhibitor. Neither salbutamol IC infusion nor acetylcholine significantly changed heart rate or blood pressure, whereas L-NMMA slightly increased blood pressure. In normal coronary arteries, salbutamol increased LD (LD max %: 11+/-2, P<0.05), APV (APV max %: 53+/-17, P<0.05), and CBF (CBF max %: 57+/-17, P<0.05), whereas L-NMMA caused a blunted APV (APV max %: 27+/-6, P<0.05) and CBF (CBF max %: 29+/-6, P<0.05) response to salbutamol. In mildly atherosclerotic coronary arteries, the salbutamol increase in LD (LD max %: 10+/-2, P<0.05), APV (APV max %: 33+/-12, P<0.05), and CBF (CBF max %: 37+/-12, P<0.05) was preserved. In stenotic coronary arteries, salbutamol induced a paradoxical reduction in LD (LD max %: -6+/-2, P<0.05), APV (APV max %: -15+/-9, P<0.05), and CBF (CBF max %: -15+/-6, P<0.05), which was no longer observed after phentolamine. Acetylcholine increased LD (LD max %: 14+/-3, P<0.05), APV (APV max %: 61+/-20, P<0.05), and CBF (CBF max %: 67+/-19, P<0.05) in normal coronary arteries. In mildly atherosclerotic coronary arteries, acetylcholine induced a significant reduction in LD (LD max %: -15+/-2, P<0.05) and no changes in APV (APV max %: -6+/-13, P=NS) and CBF (CBF max %: -10+/-13, P=NS). In stenotic coronary arteries, acetylcholine significantly reduced LD (LD max %: -15+/-3, P<0.05), APV (APV max %: -15+/-9, P<0.05), and CBF (CBF max %: -15+/-6, P<0.05).

Conclusions: In severely atherosclerotic coronary arteries, beta2-adrenergic vasodilatation is impaired, and this might contribute to alter the vasomotor balance, further precipitating myocardial ischemia during sympathetic activation.

Citing Articles

Triglycerides/High-Density Lipoprotein Ratio and Coronary Artery Disease: Results from a Large Single-Center Study.

De Luca G, Nardin M, Micari A, Kedhi E, Galasso G, Verdoia M J Clin Med. 2025; 14(4).

PMID: 40004901 PMC: 11856620. DOI: 10.3390/jcm14041371.


Current and Future Roles of Glycoprotein IIb-IIIa Inhibitors in Primary Angioplasty for ST-Segment Elevation Myocardial Infarction.

De Luca G, Verburg A, Vant Hof A, Berg J, Kereiakes D, Coller B Biomedicines. 2024; 12(9).

PMID: 39335537 PMC: 11428685. DOI: 10.3390/biomedicines12092023.


Vitamin D and Cardiovascular Diseases: From Physiology to Pathophysiology and Outcomes.

Nardin M, Verdoia M, Nardin S, Cao D, Chiarito M, Kedhi E Biomedicines. 2024; 12(4).

PMID: 38672124 PMC: 11048686. DOI: 10.3390/biomedicines12040768.


An experimental model of western diet in female Wistar rats leads to cardiac hypoxia related to a stimulated contractility.

Rigaudiere J, Jouve C, Capel F, Patrac V, Miguel B, Tournadre A J Physiol Biochem. 2024; 80(2):287-302.

PMID: 38175500 DOI: 10.1007/s13105-023-01003-w.


New Insights into Pathophysiology and New Risk Factors for ACS.

Nardin M, Verdoia M, Laera N, Cao D, De Luca G J Clin Med. 2023; 12(8).

PMID: 37109221 PMC: 10146393. DOI: 10.3390/jcm12082883.